A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, omozygous for the F508del-CFTR Mutation

Grants and Contracts Details

StatusFinished
Effective start/end date6/20/13 → 6/30/15

Funding

  • Vertex Pharmaceuticals Inc: $75,088.00